This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
CAMBRIDGE, Mass., Oct. 19, 2012 (GLOBE NEWSWIRE) --
Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), an emerging biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat debilitating and often fatal rare diseases, announced today that the company will host an investor event consisting of a company presentation and a discussion by several physicians in the field of lipidology. The event will be held on Tuesday, October 23, with the webcast scheduled to begin at approximately 3:00 p.m. EDT.
The investor event will be webcast live and may be accessed through the "
Investors" section of the Aegerion website,
Aegerion Pharmaceuticals, Inc.is an emerging biopharmaceutical company focused on the development and commercialization of novel, life-altering therapeutics to treat debilitating and often fatal rare diseases. The company's lead drug candidate, lomitapide, is in late-stage development for the treatment of Homozygous Familial Hypercholesterolemia (HoFH), a rare life-threatening disease characterized by severely elevated cholesterol levels.
Aegerion is motivated by its commitment to patients first, as well as its core values of integrity, innovation, responsibility to healthcare providers and development of employees, with a constant focus on scientific and clinical excellence. For more information, visit
CONTACT: Aegerion Pharmaceuticals, Inc.
Michael Lawless, VP, IR